Compare SBGI & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBGI | CDNA |
|---|---|---|
| Founded | 1986 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2023 | 2007 |
| Metric | SBGI | CDNA |
|---|---|---|
| Price | $15.31 | $19.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $21.80 | ★ $27.33 |
| AVG Volume (30 Days) | 399.5K | ★ 655.1K |
| Earning Date | 05-26-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,169,000,000.00 | $48,324,000.00 |
| Revenue This Year | $10.60 | $15.37 |
| Revenue Next Year | N/A | $11.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $11.89 | $10.96 |
| 52 Week High | $17.88 | $21.49 |
| Indicator | SBGI | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 48.61 |
| Support Level | $14.43 | $18.30 |
| Resistance Level | $15.62 | $20.94 |
| Average True Range (ATR) | 0.76 | 0.93 |
| MACD | 0.12 | -0.06 |
| Stochastic Oscillator | 50.09 | 65.12 |
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.